Ipsen – Individualized Therapeutic Strategies in PBC Grant RFP (2026–2027)
Educational Grants to Advance Personalized Care in Rare Liver Disease
Organization: Ipsen
Support Type: Educational grant (RFP)
Geographic Focus: United States
About the Funder
Ipsen is a global biopharmaceutical company committed to improving patient outcomes through innovative science and education. Through its grants program, Ipsen supports independent, accredited educational initiatives that address unmet healthcare needs and improve clinical practice.
What This Program Supports
This RFP focuses on Primary Biliary Cholangitis (PBC) and aims to improve clinician understanding of both biochemical disease management and patient-reported symptom burden.
Ipsen is seeking proposals for:
- Live educational programs at national congresses (2026–2027)
- Enduring educational content (minimum 12 months)
Priority topics include:
- Individualizing treatment strategies to optimize biochemical control (e.g., ALP normalization)
- Translating emerging evidence into practical clinical decision-making
- Improving routine assessment and management of symptoms such as fatigue and pruritus
- Addressing gaps where symptom burden is under-recognized in clinical care
Eligible Support Types
- Accredited continuing medical education (CME) programs
- National congress symposia and educational sessions
- Multi-channel education initiatives (live + enduring content)
Eligibility & Preferences
Eligible Applicants:
- Academic institutions
- Medical education providers
- Disease foundations and associations
- Patient advocacy organizations
- Healthcare-focused nonprofits
Ineligible Applicants:
- Individuals (including healthcare providers)
- Provider-owned practices or clinics
- Managed care organizations and pharmacy benefit managers
Preferences:
- Multi-supported (co-funded) programs
- Accredited providers in good standing
- Strong outcomes measurement and evaluation plans
Funding Amounts
💰 Ipsen will contribute up to $300,000
- Final award amounts may vary
- Budgets must be detailed, reasonable, and aligned with fair market value
Timeline & Review
📅 RFP Released: March 19, 2026
📅 Application Deadline: October 1, 2026
📅 Award Notification: October 31, 2026
📅 Program Timeline: Programs aligned with 2026–2027 national congresses
Application / Request Process
- Submit via the Ipsen Grants Portal
- Include RFP number: Ipsen-RFP-Rare-2026-02
- Required components include:
- Needs assessment and gap analysis
- Learning objectives and curriculum design
- Faculty and recruitment plan
- Evaluation and reporting strategy
- Detailed budget and funding breakdown
Apply / Learn More:
➡️ https://www.ipsen.com/us/wp-content/uploads/sites/2/2026/03/Individualized-Therapeutic-Strategies-in-PBC-Post-Date_March-19.pdf
Why This Opportunity Is a Good Fit
This opportunity is a strong fit for organizations that:
- Develop CME-accredited education for specialists
- Focus on liver disease, rare disease, or chronic condition management
- Have experience delivering national conference-based programming
- Can bridge clinical evidence and patient-centered care approaches
- Are equipped to produce long-term, scalable educational content
Corporate Grants Guide Notes
- Review Type: Competitive RFP
- Typical Lead Time: 4–6+ months before program launch
- Best Suited For: Medical education providers, academic institutions, and healthcare nonprofits with national reach
New to corporate grant fundraising?
Read our Corporate Grants for Nonprofits: Ultimate Guide to learn how corporate funding works.
